Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLBD Blue Bird	$71.16 +1.3%	$65.47	$40.45 ▼ $81.51	$2.22B	1.37	480,366 shs	392,376 shs
CRSP CRISPR Therapeutics	$51.48 -0.2%	$52.23	$39.81 ▼ $78.48	$4.98B	1.74	1.62 million shs	1.46 million shs
GDRX GoodRx	$2.65 +0.8%	$2.47	$1.77 ▼ $5.81	$900.97M	1.61	1.59 million shs	1.57 million shs
GILD Gilead Sciences	$125.50 -2.0%	$134.03	$104.46 ▼ $157.29	$159.05B	0.31	7.23 million shs	8.68 million shs
VRTX Vertex Pharmaceuticals	$445.77 +0.6%	$437.37	$362.50 ▼ $507.92	$112.43B	0.3	1.29 million shs	871,092 shs

5G Stocks: The Path Forward is Profitable

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLBD Blue Bird	+1.32%	-1.63%	+0.20%	+32.69%	+74.11%
CRSP CRISPR Therapeutics	-0.23%	-1.04%	-6.11%	+3.10%	+22.31%
GDRX GoodRx	+0.76%	-10.17%	-9.25%	+17.78%	-35.52%
GILD Gilead Sciences	-2.03%	-1.62%	-4.44%	-14.04%	+11.06%
VRTX Vertex Pharmaceuticals	+0.63%	+4.86%	+3.71%	-9.47%	-0.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLBD Blue Bird	$71.16 +1.3%	$65.47	$40.45 ▼ $81.51	$2.22B	1.37	480,366 shs	392,376 shs
CRSP CRISPR Therapeutics	$51.48 -0.2%	$52.23	$39.81 ▼ $78.48	$4.98B	1.74	1.62 million shs	1.46 million shs
GDRX GoodRx	$2.65 +0.8%	$2.47	$1.77 ▼ $5.81	$900.97M	1.61	1.59 million shs	1.57 million shs
GILD Gilead Sciences	$125.50 -2.0%	$134.03	$104.46 ▼ $157.29	$159.05B	0.31	7.23 million shs	8.68 million shs
VRTX Vertex Pharmaceuticals	$445.77 +0.6%	$437.37	$362.50 ▼ $507.92	$112.43B	0.3	1.29 million shs	871,092 shs

5G Stocks: The Path Forward is Profitable

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLBD Blue Bird	+1.32%	-1.63%	+0.20%	+32.69%	+74.11%
CRSP CRISPR Therapeutics	-0.23%	-1.04%	-6.11%	+3.10%	+22.31%
GDRX GoodRx	+0.76%	-10.17%	-9.25%	+17.78%	-35.52%
GILD Gilead Sciences	-2.03%	-1.62%	-4.44%	-14.04%	+11.06%
VRTX Vertex Pharmaceuticals	+0.63%	+4.86%	+3.71%	-9.47%	-0.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLBD Blue Bird	2.63	Moderate Buy	$77.80	9.33% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$65.47	27.18% Upside
GDRX GoodRx	2.13	Hold	$3.81	43.87% Upside
GILD Gilead Sciences	2.86	Moderate Buy	$156.93	25.04% Upside
VRTX Vertex Pharmaceuticals	2.88	Moderate Buy	$555.91	24.71% Upside

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, BLBD, GDRX, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2026	BLBD Blue Bird	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$86.00
6/9/2026	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/8/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform
6/1/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$122.00
6/1/2026	BLBD Blue Bird	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$86.00
6/1/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
5/28/2026	GILD Gilead Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/27/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
5/27/2026	VRTX Vertex Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$542.00
5/20/2026	GDRX GoodRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
5/20/2026	GILD Gilead Sciences	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$165.00

(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLBD Blue Bird	$1.48B	1.52	$4.76 per share	14.94	$8.06 per share	8.83
CRSP CRISPR Therapeutics	$3.51M	1,414.60	N/A	N/A	$20.17 per share	2.55
GDRX GoodRx	$796.85M	1.14	$0.40 per share	6.57	$1.81 per share	1.46
GILD Gilead Sciences	$29.44B	5.29	$10.26 per share	12.23	$18.23 per share	6.88
VRTX Vertex Pharmaceuticals	$12.00B	9.43	$17.69 per share	25.20	$73.57 per share	6.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLBD Blue Bird	$127.72M	$4.07	17.48	15.04	0.98	8.91%	53.68%	22.19%	8/5/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$6.22	N/A	N/A	N/A	-13,856.54%	-25.66%	-20.39%	8/3/2026 (Estimated)
GDRX GoodRx	$30.44M	$0.06	44.17	13.25	1.22	2.61%	7.90%	3.23%	8/5/2026 (Estimated)
GILD Gilead Sciences	$8.51B	$7.34	17.10	13.17	N/A	30.99%	48.19%	18.28%	8/6/2026 (Estimated)
VRTX Vertex Pharmaceuticals	$3.95B	$16.86	26.44	23.50	1.89	35.51%	23.86%	17.13%	8/3/2026 (Estimated)

Latest CRSP, VRTX, BLBD, GDRX, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	GILD Gilead Sciences	$1.91	$2.03	+$0.12	$1.61	$6.91 billion	$6.96 billion
5/6/2026	Q2 2026	BLBD Blue Bird	$0.8770	$1.00	+$0.1230	$0.90	$335.23 million	$352.64 million
5/6/2026	Q1 2026	GDRX GoodRx	$0.07	$0.07	N/A	N/A	$185.40 million	$194.01 million
5/4/2026	Q1 2026	CRSP CRISPR Therapeutics	-$1.2185	-$1.28	-$0.0615	-$1.28	$6.06 million	$1.46 million
5/4/2026	Q1 2026	VRTX Vertex Pharmaceuticals	$4.24	$4.47	+$0.23	$4.02	$2.99 billion	$2.99 billion
3/31/2026	Q1 2026	CRSP CRISPR Therapeutics	N/A	-$1.28	N/A	-$1.28	N/A	$1.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLBD Blue Bird	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.28	2.61%	+3.04%	44.69%	10 Years
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CRSP, VRTX, BLBD, GDRX, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GILD Gilead Sciences	quarterly	$0.82	2.45%	6/15/2026	6/15/2026	6/29/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLBD Blue Bird	0.28	1.83	1.27
CRSP CRISPR Therapeutics	0.32	17.97	17.96
GDRX GoodRx	0.78	1.47	1.47
GILD Gilead Sciences	0.89	1.97	1.77
VRTX Vertex Pharmaceuticals	N/A	3.02	2.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLBD Blue Bird	93.59%
CRSP CRISPR Therapeutics	69.20%
GDRX GoodRx	63.77%
GILD Gilead Sciences	83.67%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BLBD Blue Bird	1.10%
CRSP CRISPR Therapeutics	4.10%
GDRX GoodRx	5.87%
GILD Gilead Sciences	0.30%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLBD Blue Bird	2,012	31.65 million	31.30 million	Optionable
CRSP CRISPR Therapeutics	460	96.45 million	92.50 million	Optionable
GDRX GoodRx	950	342.57 million	322.47 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
VRTX Vertex Pharmaceuticals	6,400	253.80 million	253.30 million	Optionable

CRSP, VRTX, BLBD, GDRX, and GILD Headlines

Recent News About These Companies

Franklin Resources Inc. Increases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

5 minutes ago | marketbeat.com

Carmen Bozic Sells 1,745 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

14 minutes ago | insidertrades.com

Deutsche Bank AG Has $801.94 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

1 hour ago | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Consensus Recommendation of "Moderate Buy" by Analysts

3 hours ago | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Moderate Buy" from Brokerages

3 hours ago | marketbeat.com

Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 1,745 Shares

June 9 at 5:10 PM | marketbeat.com

O Shaughnessy Asset Management LLC Buys 11,564 Shares of Vertex Pharmaceuticals Incorporated $VRTX

June 9 at 6:02 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Cerity Partners LLC

June 9 at 4:11 AM | marketbeat.com

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

June 8 at 6:41 PM | fool.com

WINTON GROUP Ltd Purchases New Shares in Vertex Pharmaceuticals Incorporated $VRTX

June 7 at 7:14 AM | marketbeat.com

ING Groep NV Has $36.78 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

June 7 at 6:40 AM | marketbeat.com

Los Angeles Capital Management LLC Boosts Position in Vertex Pharmaceuticals Incorporated $VRTX

June 7 at 6:39 AM | marketbeat.com

Clearbridge Investments LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX

June 7 at 4:36 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX is Capital World Investors' 10th Largest Position

June 7 at 4:36 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Position Increased by Capital Research Global Investors

June 7 at 4:35 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Capital International Sarl

June 7 at 4:28 AM | marketbeat.com

Capital International Ltd. CA Sells 25,675 Shares of Vertex Pharmaceuticals Incorporated $VRTX

June 7 at 4:27 AM | marketbeat.com

Capital International Inc. CA Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

June 7 at 4:27 AM | marketbeat.com

Capital International Investors Increases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

June 7 at 4:15 AM | marketbeat.com

Capital Group Investment Management PTE. LTD. Sells 5,421 Shares of Vertex Pharmaceuticals Incorporated $VRTX

June 7 at 3:31 AM | marketbeat.com

Assessing Vertex Pharmaceuticals (VRTX) Valuation After Mixed Recent Returns And Long Term Shareholder Gains

June 6, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP, VRTX, BLBD, GDRX, and GILD Company Descriptions

Blue Bird NASDAQ:BLBD

$71.16 +0.93 (+1.32%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$68.55 -2.61 (-3.67%)

As of 05:37 AM Eastern

Blue Bird Corporation, together with its subsidiaries, designs, engineers, manufactures, and sells school buses in the United States, Canada, and internationally. The company operates through two segments, Bus and Parts. It offers Type C, Type D, and specialty buses; and alternative power options through its propane powered, gasoline powered, compressed natural gas powered, and electric powered school buses, as well as diesel engines. The company also sells replacement bus parts; and provides financing services and extended warranties related to its products. Blue Bird Corporation sells its products through drop ship and a network of dealers, as well as directly to fleet operators, the United States government, and state governments; independent service centers; and maintains a parts distribution center. Blue Bird Corporation was founded in 1927 and is headquartered in Macon, Georgia.

CRISPR Therapeutics NASDAQ:CRSP

$51.48 -0.12 (-0.23%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$50.50 -0.98 (-1.90%)

As of 05:51 AM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

GoodRx NASDAQ:GDRX

$2.65 +0.02 (+0.76%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$2.68 +0.03 (+1.13%)

As of 05:12 AM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Gilead Sciences NASDAQ:GILD

$125.50 -2.60 (-2.03%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$125.50 0.00 (0.00%)

As of 05:52 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Vertex Pharmaceuticals NASDAQ:VRTX

$445.77 +2.81 (+0.63%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$445.00 -0.77 (-0.17%)

As of 05:50 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, BLBD, GDRX, and GILD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRSP, VRTX, BLBD, GDRX, and GILD Earnings

Compare Dividends

Latest CRSP, VRTX, BLBD, GDRX, and GILD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRSP, VRTX, BLBD, GDRX, and GILD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP, VRTX, BLBD, GDRX, and GILD Company Descriptions

Blue Bird NASDAQ:BLBD

CRISPR Therapeutics NASDAQ:CRSP

GoodRx NASDAQ:GDRX

Gilead Sciences NASDAQ:GILD

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools